Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug behemoth Pfizer
With that in mind, let's take a closer look at Pfizer's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||New York (1849)|
|Market Cap||$168.7 billion|
|Trailing-12-Month Revenue||$68.8 billion|
|Management||Chairman/CEO Ian Read
CFO Frank D'Amelio
|Return on Equity (Average, Past 3 Years)||10.5%|
|Cash/Debt||$29.0 billion / $41.1 billion|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 90% of the 6,086 members who have rated Pfizer believe the stock will outperform the S&P 500 going forward.
Expiring patents are already priced in so that will have no effect on their stock price. They have a history of creating blockbuster drugs and there are more to come. ... [In 2010] they surpassed $1 billion in annual revenue in both China and Brazil for the first time in the company's history. These are two of the largest emerging pharmaceutical markets globally so continued growth is expected. This is a dependable, low risk company, with growth potential and a great dividend. OUTPERFORM!
What do you think about Pfizer, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Pfizer and Novartis. Try any of our Foolish newsletter services free for 30 days.